HOYA Vision Care Reveals Latest Insights to Advance Myopia Management at International Myopia Conference 2022

HOYA’s evidence-based approach for successful myopia management helps eye care professionals make informed clinical decisions


HOYA Vision Care, a leader in optical technology innovation, participated as an official diamond sponsor in the International Myopia Conference (IMC) held 4-7 September 2022 in Rotterdam, The Netherlands. During the conference, HOYA hosted a myopia symposium where experts shared their latest findings of the clinical application of the MiYOSMART spectacle lens and its role in myopia management.

Under the theme –The Latest Insights to Advance Myopia Management – renowned key opinion leaders shared new European data and discussed topics including emmetropic eye growth,
combination treatment as well as relative peripheral refraction (RPR).

Dr. Andrea Lembo of the University Hospital San Giuseppe Multimedica in Milan, Italy shared the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% Atropine drops in European myopic children and adolescents.1

The results demonstrated that over one-year, axial elongation and myopia progression were reduced with maximum effect using the combination treatment.1 Prof. Hakan Kaymak of the Internationale Innovative Ophthalmochirurgie in Duesseldorf, Germany presented the findings of his study on axial length growth under treatment with MiYOSMART spectacle lenses.

The data of German children wearing MiYOSMART spectacle lenses reconfirmed previous clinical study results.1

Further findings showed that children adapt very well to MiYOSMART spectacle lenses with no safety concerns even in combination with low-dose atropine.1

In addition, Professor Carly Lam of The Hong Kong Polytechnic University shared how myopia control effect may be influenced by baseline relative peripheral refraction in children wearing the MiYOSMART spectacle lens with D.I.M.S. Technology.1

The results showed that myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR.1

“We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022,” said May Zhang, Global Head of Professional Affairs. “HOYA Vision Care continues to be a leader in addressing myopia in children and championing new practices like the successful combination treatment of the MiYOSMART spectacle lens and Atropine drops as well as continued support of clinical studies in multiple countries to help eye care professionals make informed decisions.”

Since its launch in 2018, MiYOSMART is available in 28 markets with over two million spectacle lenses purchased by parents around the world.2

PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S. 1 Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium ” New Insights to Advance Myopia Management”: Axial length growth under therapy with MiYOSMART spectacle lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated
Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC) 2022, September 4, Rotterdam, The Netherlands. 2 Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.